To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Glycoprotein IIb/IIIa inhibitorsIn medicine, glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, is a class of antiplatelet agents. Additional recommended knowledgeSeveral GpIIb/IIIa inhibitors exist:
UseGlycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement). They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets. They may also be used to treat acute coronary syndromes, without percutaneous coronary intervention, depending on TIMI risk. They should be given intravenously. The oral form is associated with increased mortality and hence should not be given. HistoryTheir development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.[1] References
|
||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Glycoprotein_IIb/IIIa_inhibitors". A list of authors is available in Wikipedia. |